AZD 3241

Drug Profile

AZD 3241

Alternative Names: AZD-3241

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antiparkinsonians; Pyrimidinones; Small molecules
  • Mechanism of Action Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple system atrophy; Parkinson's disease

Most Recent Events

  • 11 Jul 2017 Discontinued - Phase-II for Multiple system atrophy in France, Sweden, USA, Italy, United Kingdom, Finland and Austria (PO) (AstraZeneca pipeline, July 2017)
  • 01 Sep 2016 AstraZeneca completes a phase II trial in Multiple system atrophy in USA, Austria, Finland, France, Italy, Sweden and United Kingdom (NCT02388295)
  • 01 Apr 2015 AZD 3241 is still in phase-II development for Multiple system atrophy in United Kingdom, Italy, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top